성인 급성골수성 백혈병의 DAV ( Doxorubicin Ara - C and Vp - 16 ) 복합화학요법

Abstract

To evaluate the therapeutic effect and usefulness of DAV combination chemotherapy, 12 patients with adult acute myelogenous leukemia were treated with a DAV (Doxorubicin 45 ㎎/㎡ 4, days 3-5, Ara-C 100 ㎎/㎡ 4, days 1-8 and VP-16 100 ㎎/㎡ 4, days 6-8) regimen for remission induction. The results were as follows: 1) The rate of complete remission was 10/13 (76.9%) including one case of re-induction chemotherapy. 2) The median remission duration and the median survival duration in-completely remitted patients were 8 months (1-16 months) and 10 months (2-25 months), respectively. 3) Two among the 9 remitted patients were relapsed (22%). 4) The 2-year survival rates of all patients, the completely remitted patients and the in-completely remitted patients were 33%, 50% and 0%, respectively. 5) The drug toxicities of grade 3 or more (grade 2 or more in anorexia, nausea and alopecia) according to ECOG (Eastern Cooperative Oncology Group) toxicity criteria were as follows: leukopenia-11/12 (92%), anorexia and nausea-8/12 (67%), alopecia-8/12 (67%), mucositis and stomatitis-7/12 (58%) and hemorrhage-5/12 (42%). Thus, we conclude that DAV combination chemotherapy is one of the useful and encouraging therapeutic regimens in remission induction of adult acute myelogenous leukemia.